RA0211

antibody from Oursmab

Targeting: ENG CD105, END, HHT1, ORW, ORW1

Western blot (Data presented on provider website)

ELISA (Recommended by provider)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0211

Provider

Oursmab

Product name

Carotuximab (Biosimilar Reference Antibody) (ENG)

Antibody type

Monoclonal

Description

Carotuximab (also known as TRC105) is an investigational chimeric monoclonal antibody developed as an anti-angiogenic agent for the treatment of solid tumors. It is designed to inhibit the formation of new blood vessels that supply tumors with oxygen and nutrients. Clinical trials have evaluated its efficacy, both as a monotherapy and in combination with other anti-cancer therapies such as VEGF inhibitors or chemotherapy, in a range of advanced cancers including soft tissue sarcoma, hepatocellular carcinoma, mesothelioma, and glioblastoma. However, its development has faced challenges, and it has not yet achieved widespread regulatory approval for clinical use.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.